These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33128043)

  • 1. Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.
    Abd-Elrahman I; Nassar T; Khairi N; Perlman R; Benita S; Ben Yehuda D
    Oncogene; 2021 Jan; 40(2):334-344. PubMed ID: 33128043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of Apoptosis-related Protein Livin and Caspase-3 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].
    Jin L; Sui YX; Chen ZZ; Li YH; Wang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1664-1669. PubMed ID: 29262894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin.
    Nachmias B; Lazar I; Elmalech M; Abed-El-Rahaman I; Asshab Y; Mandelboim O; Perlman R; Ben-Yehuda D
    Apoptosis; 2007 Jul; 12(7):1129-42. PubMed ID: 17294084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. tLivin displays flexibility by promoting alternative cell death mechanisms.
    Shiloach T; Berens C; Danke C; Waiskopf O; Perlman R; Ben-Yehuda D
    PLoS One; 2014; 9(6):e101075. PubMed ID: 24960127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity.
    Abd-Elrahman I; Hershko K; Neuman T; Nachmias B; Perlman R; Ben-Yehuda D
    Cancer Res; 2009 Jul; 69(13):5475-80. PubMed ID: 19549891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
    J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma.
    Sugihara E; Hashimoto N; Osuka S; Shimizu T; Ueno S; Okazaki S; Yaguchi T; Kawakami Y; Kosaki K; Sato TA; Okamoto S; Saya H
    Cancer Res; 2020 Oct; 80(20):4439-4450. PubMed ID: 32928920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
    Wu X; Ban C; Deng W; Bao X; Tang N; Wu Y; Deng Z; Xiong J; Zhao Q
    Mol Cancer; 2024 Jul; 23(1):144. PubMed ID: 39004737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the truncated form of Livin reveals a complex interaction with caspase-3.
    Liu GH; Wang C; Ding ZY
    Int J Oncol; 2013 Jun; 42(6):2037-45. PubMed ID: 23563149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
    Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Livin, a novel marker in lymphoma type distinction.
    Tanhaei AP; Ziaei A; Mazrouei S; Keyhanian K; Salehi M
    Ann Diagn Pathol; 2014 Jun; 18(3):157-62. PubMed ID: 24767895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress on Livin protein: an inhibitor of apoptosis.
    Yan B
    Mol Cell Biochem; 2011 Nov; 357(1-2):39-45. PubMed ID: 21617971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
    Feng L; Xu X; Zhao K
    Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells.
    Guan HP; Sun JZ; Feng XL; Chen JS; Chen FJ; Cheng XF; Liu XW; Ni B
    Mol Med Rep; 2016 Feb; 13(2):1821-6. PubMed ID: 26708654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
    Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
    Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.